8-K: Journey Medical Reports Q1 2025 Financial Results; Emrosi Launch Off to Strong Start

Journey Medical Corporation announced its Q1 2025 financial results, highlighting a strong start to the commercial launch of Emrosi and consistent revenue compared to the previous year.

Summary

• Journey Medical Corporation reported its financial results for the first quarter ended March 31, 2025.
• Revenue for Q1 2025 was $13.1 million, consistent with the $13.0 million reported in Q1 2024.
• The Q1 2025 revenue includes $2.1 million from the launch of Emrosi.
• Gross margin increased to 64% in Q1 2025 from 54% in the prior year due to lower product costs and non-recurring charges in the prior year.
• Research and development costs were nil in Q1 2025, compared to $7.9 million in Q1 2024 due to the completion of Emrosi pre-approval expenses.
• Selling, general, and administrative expenses increased by $2.1 million to $10.569 million due to the Emrosi launch.
• The company's net loss was $4.1 million, or $(0.18) per share, compared to a net loss of $10.4 million, or $(0.53) per share, for Q1 2024.
• Cash and cash equivalents were $21.1 million as of March 31, 2025, compared to $20.3 million at the end of 2024.
• The company expects 2025 to be a transformational year, driving the business to sustainable positive EBITDA and profitability.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the successful launch of Emrosi, improved gross margins, and reduced net loss, although the company is still operating at a loss.

Positives

• The commercial launch of Emrosi is off to a strong start, contributing $2.1 million in revenue.
• Gross margin improved significantly to 64%.
• Net loss decreased substantially from $10.4 million to $4.1 million.
• The company's cash position remains strong at $21.1 million.
• Emrosi's Phase 3 clinical trial results were published in JAMA Dermatology.
• Emrosi was included in the National Rosacea Society's Rosacea Treatment Algorithms.

Negatives

• The company still reported a net loss of $4.1 million.
• Selling, general, and administrative expenses increased due to the Emrosi launch.

Risks

• The company's forward-looking statements are subject to risks and uncertainties that could negatively affect their business, operating results, financial condition, and stock price.
• Competition could limit the commercial opportunity and profitability of their products.
• The company relies on third parties for several aspects of their operations.
• The company's success depends on the successful commercialization of Emrosi and any future product candidates.

Future Outlook

The company believes that 2025 will be a transformational year as they drive the business to sustainable positive EBITDA and profitability.

Management Comments

• The first quarter of 2025 was highly productive, as our in-line dermatology products continue to perform and the launch of Emrosi, our best-in-class oral rosacea treatment, is off to a strong start, said Claude Maraoui, Journey Medicals Co-Founder, President and Chief Executive Officer.
• Financially, we remain in a strong position with $21.1 million in cash as of March 31, an improvement in our gross margin, and overall operating spend down year-over-year, Mr. Maraoui continued.

Industry Context

Journey Medical operates in the dermatology pharmaceutical market, focusing on FDA-approved prescription products. The launch of Emrosi positions them to compete with existing rosacea treatments like Oracea.

Comparison to Industry Standards

• Journey Medical's focus on dermatology aligns with companies like Galderma, which markets Oracea, a competitor to Emrosi.
• The company's strategy of acquiring and commercializing FDA-approved products is similar to that of other specialty pharmaceutical companies.
• The publication of Emrosi's Phase 3 clinical trial results in JAMA Dermatology provides credibility and visibility within the medical community, similar to how other pharmaceutical companies promote their products.

Management Changes

Related Party Transactions

• The company reported $399 thousand due to related party as of March 31, 2025.

Stakeholder Impact

• Shareholders may be encouraged by the improved financial performance and the successful launch of Emrosi.
• Employees may benefit from the company's growth and expansion.
• Customers (patients) now have access to a new treatment option for rosacea.
• Suppliers may see increased demand for their products and services.

Next Steps

• Journey Medical management will conduct a conference call and audio webcast on May 14, 2025, at 4:30 p.m. ET.

Key Dates

Keywords

Journey Medical, Emrosi, Financial Results, Dermatology, Rosacea, Revenue, Gross Margin, Net Loss